US stock · Healthcare sector · Biotechnology
Company Logo

ImmunoGen, Inc.

IMGNNASDAQ

4.58

USD
-0.12
(-2.55%)
Market Closed
-7.22P/E
-6Forward P/E
-0.36P/E to S&P500
1.011BMarket CAP
- -Div Yield
Upcoming Earnings
27 Oct-31 Oct
Shares Short
8/31/22
12.31M
Short % of Float
5.60%
Short % of Shares Outs.
5.58%
% Held by Insiders
0.40%
% Held by Institutions
92.08%
Beta
0.90
PEG Ratio
- -
52w. high/low
7.77/3.10
Avg. Daily Volume
3.01M
Return %
Stock
S&P 500
1 year
(23.79)
(16.94)
3 years
59.03
24.12
5 years
(32.25)
47.77
Scale: |
High
Low
6.24
3.80
5.80
2.47
10.13
3.85
10.90
4.96
16.20
8.06
18.10
10.85
20.25
12.55
17.80
5.34
19.43
5.85
13.39
1.51
8.84
1.84
13.41
3.80
6.13
1.76
7.87
1.95
10.88
4.72
7.63
3.10
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.78
0.92
0.94
0.55
0.24
0.28
0.21
0.42
0.70
0.99
0.69
1.18
0.38
0.55
0.75
0.34
0.39
Earnings per share
(0.43)
(0.45)
(0.75)
(0.63)
(0.87)
(0.85)
(0.95)
(0.87)
(0.83)
(0.71)
(1.67)
(0.98)
(1.21)
(0.70)
(0.25)
(0.68)
(0.45)
FCF per share
(0.40)
(0.43)
(0.89)
(0.30)
(0.72)
(0.15)
(0.48)
(0.76)
(0.72)
(0.73)
(1.55)
0.07
(1.23)
(0.62)
(0.45)
(0.83)
(0.81)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.05
0.05
0.42
0.04
0.03
0.03
0.04
0.04
0.10
0.09
0.12
0.01
0.04
0.02
0.01
0.01
0.00
Book Value per sh.
1.76
1.40
1.29
1.31
1.73
2.03
1.09
1.45
0.89
0.41
(0.95)
(0.18)
0.08
(0.51)
0.51
1.58
1.03
Comm.Shares outs.
41
42
43
51
59
69
77
84
85
86
87
98
140
148
176
206
232
Avg. annual P/E ratio
(9.5)
(11.0)
(5.2)
(11.5)
(9.2)
(13.3)
(14.6)
(18.6)
(14.7)
(16.0)
(3.0)
(5.3)
(7.6)
(4.6)
(18.6)
(10.2)
(7.2)
P/E to S&P500
(0.5)
(0.6)
(0.2)
(0.2)
(0.4)
(0.8)
(1.0)
(1.1)
(0.8)
(0.8)
(0.1)
(0.2)
(0.3)
(0.2)
(0.5)
(0.3)
(0.4)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
32
38
40
28
14
19
16
36
60
86
60
115
53
82
132
70
89
Operating margin
(66.6)%
(58.2)%
(84.8)%
(113.7)%
(367.5)%
(311.8)%
(447.9)%
(205.5)%
(119.4)%
(63.7)%
(208.3)%
(51.1)%
(302.1)%
(112.0)%
(16.9)%
(179.0)%
(246.6)%
Depreciation (m)
3
3
4
5
5
5
5
5
5
6
5
6
7
4
2
- -
2
Net profit (m)
(18)
(19)
(32)
(32)
(51)
(58)
(73)
(73)
(71)
(61)
(145)
(96)
(169)
(104)
(44)
(139)
(98)
Income tax rate
(0.1)%
(0.2)%
(0.1)%
0.3%
0.5%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net profit margin
(55.6)%
(49.7)%
(79.6)%
(114.1)%
(365.1)%
(301.9)%
(448.2)%
(204.9)%
(119.1)%
(71.0)%
(241.4)%
(83.2)%
(315.9)%
(126.6)%
(33.5)%
(199.4)%
(149.4)%
Working capital (m)
74
58
46
66
103
187
150
182
130
256
193
221
208
131
202
378
307
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
100
2
2
2
19
- -
13
Equity (m)
72
58
55
67
102
140
84
122
76
35
(82)
(18)
11
(76)
90
326
250
ROIC
(21.4)%
(28.7)%
(43.9)%
(35.7)%
(41.3)%
(28.7)%
(44.7)%
(37.4)%
(49.5)%
(19.9)%
(55.3)%
(33.2)%
(70.4)%
(55.2)%
(9.1)%
(29.7)%
(27.1)%
Return on capital
(18.9)%
(23.6)%
(38.4)%
(31.8)%
(37.3)%
(26.8)%
(40.7)%
(34.1)%
(43.2)%
(17.6)%
(43.4)%
(26.9)%
(53.5)%
(37.0)%
(6.0)%
(24.0)%
(21.5)%
Return on equity
(24.6)%
(32.5)%
(57.9)%
(47.8)%
(49.9)%
(41.6)%
(87.4)%
(59.8)%
(94.3)%
(173.0)%
176.0%
536.5%
(1,538.9)%
136.8%
(49.5)%
(42.8)%
(39.3)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
1 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 172
Total assets
$ 422
Long-term debt
$ 13
Cash and equiv.
$ 374
Goodwill
$ - -
Retained earnings
$ (1,557)
Common stock
253
Enterprise Value
$ 650
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
176
294
479
Receivables
27
22
- -
Inventory
- -
- -
- -
Other
5
126
303
Current assets
209
324
479
Acc. Payable
10
10
- -
Debt due
3
5
- -
Other
65
108
101
Current liabilities
77
122
101
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(47.20)%
3.46%
33.89%
Cash flow
114.81%
(668.54)%
(288.20)%
Earnings
213.94%
48.52%
31.25%
Dividends
- -
- -
- -
Book value
263.50%
(227.31)%
(152.03)%
Insider Trading
Type
Shares
Date
Mccain Tracey L
Award
44,000
11/15/22
Mccain Tracey L
Award
30,000
11/15/22
Mitchell Dean J
Award
3,333
06/30/22
Goldberg Mark Alan
Award
3,750
06/30/22
Mccain Tracey L
Award
3,055
06/30/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
13
15
18
86
132
2021
16
17
9
28
70
2022
38
14
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.17)
(0.14)
(0.13)
0.18
(0.25)
2021
(0.17)
(0.15)
(0.18)
(0.18)
(0.68)
2022
(0.10)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Mark Enyedy
Full-time employees:
106
City:
Boston
Address:
830 WINTER ST
IPO:
Nov 17, 1989
Website:
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.